Here, we demonstrated that an LRP-1 agonistic peptide, SP16, which inhibits ROS production, prevented NAFLD-induced depletion of CD4+ T cells in the liver and spleen [19,20,21]. This evidence concerns the gene LRP1 and metabolic dysfunction-associated steatotic liver disease.